Information Provided By:
Fly News Breaks for November 25, 2019
CHE
Nov 25, 2019 | 07:45 EDT
Oppenheimer analyst Michael Wiederhorn raised his price target for Chemed to $470 from $440 and maintained an Outperform rating after attending meetings with Chemed management, saying he believes the story remains on track as the re-basing benefit is set to take effect starting in Q4. Additionally, the analyst tells investors in a research note that Chemed continues to generate strong organic growth trends, supported by strong cash flow and compelling capital deployment trends.
News For CHE From the Last 2 Days
CHE
CHE
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.